Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 5, 2007, Pages 598-600

  Kumarasamy, N ^a   Venkatesh, Kartik K ^b   Devaleenal, Bella ^a   Palanivel, Vidhya ^a   Cecelia, Anitha J ^a   Muthu, Sundaram ^a   Yepthomi, Tokugha ^a   Mayer, Kenneth H ^c   Flanigan, Timothy ^c  

^a YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^b BROWN UNIVERSITY   (United States)

^c MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EFAVIRENZ; LIVER ENZYME; NEVIRAPINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG SAFETY; DRUG SUBSTITUTION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INDIA; LETTER; LIVER TOXICITY; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COSTS AND COST ANALYSIS; FEMALE; HIV; HIV INFECTIONS; HUMANS; INDIA; LIVER; LIVER DISEASES; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 34548056370     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318074ef99     Document Type: Letter

References (6)

1. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach - 2003 revision. Available at: http://www.who.int/hiv/pub/prev_care/en/ arvrevision2003en.pdf. Accessed December 30, 2006.
2. Puro V, Soldani F, De Carli G, et al. Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. AIDS. 2003;17:1988-1990.
3. Ena J, Amador C, Benito C, et al. Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS. 2003;14:776-781.
4. Boehringer Ingelheim. Available at: http://www.boehringer-ingelheim.com/ hiv/prod/login.htm. Accessed December 30, 2006.
5. Mocroft A, Lacombe K, Rockstroh J, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced patients with high and low CD4 counts. Presented at: XVI International AIDS Conference; Toronto; 2006.
6. AIDS Clinical Trials Group. Table for Grading the Severity of Adult Adverse Experiences. Rockville, MD: National Institutes of Health, Division of AIDS; 2004.